Substantive Updates Part Four: Key Regulatory and Pricing Developments Affecting How Life Sciences Companies Bring Products to Market
What is it about?
- Understanding what the new patient-centric drug and device development process means to manufacturers
- The year of diversity in clinical trials: updates on key initiatives to ensure the women, racial and ethnic minorities, and the elderly are not
underrepresented in trials
- Delving into recent changes to key approval pathways: biosimilars, drug-device combination products, 3D products and more
- Building a strategy for pricing and reimbursement of products in light of recent controversies including Turing and Valeant